tradingkey.logo
tradingkey.logo
Search

enGene Holdings Inc

ENGN
Add to Watchlist
2.410USD
+0.130+5.70%
Close 11-13 16:00(ET)
161.52MMarket Cap
LossP/E TTM

About enGene Holdings Inc Company

enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

enGene Holdings Inc Profile

Ticker SymbolENGN
Company nameenGene Holdings Inc
IPO dateDec 10, 2021
CEOCooper (Ronald Harold Wilfred)
Number of employees56
Security typeOrdinary Share
Fiscal year-endDec 10
Address4868 Rue Levy, Suite 220
CitySAINT-LAURENT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeH4R 2P1
Phone15143324888
Websitehttps://engene.com/
Ticker SymbolENGN
IPO dateDec 10, 2021
CEOCooper (Ronald Harold Wilfred)

Company Executives of enGene Holdings Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Katherine Chan, M.D.
Dr. Katherine Chan, M.D.
Executive Director - Urology Clinical Lead
Executive Director - Urology Clinical Lead
--
--
Ms. Amy Pott
Ms. Amy Pott
Chief Global Commercialization Officer
Chief Global Commercialization Officer
--
--
Dr. William Grossman, M.D., Ph.D.
Dr. William Grossman, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matthew Boyd
Mr. Matthew Boyd
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Ms. Jill Buck
Ms. Jill Buck
Chief Development Officer
Chief Development Officer
--
--
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Interim Chief Business Officer
Interim Chief Business Officer
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Erik Goluboff, M.D.
Dr. Erik Goluboff, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Joan Connolly
Ms. Joan Connolly
Chief Technology Officer
Chief Technology Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Katherine Chan, M.D.
Dr. Katherine Chan, M.D.
Executive Director - Urology Clinical Lead
Executive Director - Urology Clinical Lead
--
--
Ms. Amy Pott
Ms. Amy Pott
Chief Global Commercialization Officer
Chief Global Commercialization Officer
--
--
Dr. William Grossman, M.D., Ph.D.
Dr. William Grossman, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matthew Boyd
Mr. Matthew Boyd
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Ms. Jill Buck
Ms. Jill Buck
Chief Development Officer
Chief Development Officer
--
--

FAQs

Who are the top five shareholders of enGene Holdings Inc?

The top five shareholders of enGene Holdings Inc are: Mr. Wouter Joustra
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.